FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

In one of the first large-scale analyses of antibody-drug conjugates (ADCs) by race, a study presented at the recent American Society of Clinical Oncology (ASCO) meeting found that Black patients with ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

Experts Discuss Treatment Deescalation for HER2-Positive Early Breast Cancer — Removing carboplatin may preserve outcomes while reducing side effects ...

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein.

What progress has been made in understanding resistance to endocrine therapy? Insights into the management of patients with HER2-positive advanced breast cancer are presented.

“The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU ...